Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 5;19(1):772.
doi: 10.1186/s12885-019-5984-7.

Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study

Milena Casula  1 , Panagiotis Paliogiannis  2 , Fabrizio Ayala  3 , Vincenzo De Giorgi  4 , Ignazio Stanganelli  5 , Mario Mandalà  6 , Maria Colombino  1 , Antonella Manca  1 , Maria Cristina Sini  1 , Corrado Caracò  3 , Paolo Antonio Ascierto  3 , Rosanna Rita Satta  2 ; Melanoma Unit of Sassari (MUS); Amelia Lissia  2 , Antonio Cossu  2 , Giuseppe Palmieri  7 ; Italian Melanoma Intergroup (IMI)
Collaborators, Affiliations

Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study

Milena Casula et al. BMC Cancer. .

Abstract

Introduction: Multiple primary melanomas (MPM) occur up to 8% of patients with cutaneous malignant melanoma (CMM). They are often sporadic harbouring several somatic mutations, but also familial cases harbouring a CDKN2A germline mutation have been describe in Caucasian populations. The aim of this study was to investigate the incidence, the distribution patterns and the impact of known and unknown germline and somatic mutations in patients with MPM from Italy.

Materials and methods: One-hundred and two MPM patients were enrolled for germline mutation analysis, and five patients with at least four MPMs were identified for somatic mutation analysis. The demographic, pathologic and clinical features were retrieved from medical records. Molecular analysis for both germline and somatic mutations was performed in genomic DNA from peripheral blood and tissue samples, respectively, through a next generation sequencing approach, using a specific multiple-gene panel constructed by the Italian Melanoma Intergroup for somatic analysis and a commercial cancer hotspot panel for somatic analysis.

Results: CDKN2A mutations were detected in 6/16 (37.5%) and 3/86 (3.5%) MPM cases with and without family history for melanoma, respectively. Furthermore, multiple MC1R and, to a lesser extent, ATM variants have been identified. BAP1 variants were found only in MPM patients from southern Italy. The most frequent somatic variants were the pathogenic BRAFV600E and TP53, followed by KIT, PIK3CA, KDR, and NRAS. Single APC, ERBB4, MET, JAK3 and other variants with unknown function were also detected.

Conclusions: CDNK2A mutation is the most relevant susceptibility mutation in Italian patients with MPM, especially those with a family history for CMM. The prevalence of this mutation and other sequence variants identified in this study varies among specific sub-populations. Furthermore, some heterogeneity in driver somatic mutations between sporadic MPMs has been observed, as well as in a number of associated sequence variants the clinical impact of which needs to be further elucidated.

Keywords: BRAF; CDKN2A; Cancer; Melanoma; Mutations; NGS; Skin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The Italian Melanoma Intergroup (IMI Germinal DNA panel) used for genetic testing. Amplicons: 190 (size range, 125–375 bp); Coverage: 99.08%; Panel size: 53.34 kb. In gray, the genes covered for the entire coding sequences
See this image and copyright information in PMC

References

    1. Cossu A, Casula M, Cesaraccio R, Lissia A, Colombino M, Sini MC, et al. Epidemiology and genetic susceptibility of malignant melanoma in North Sardinia, Italy. Eur J Cancer Prev. 2017;26:263–267. doi: 10.1097/CEJ.0000000000000223. - DOI - PubMed
    1. Sini MC, Doneddu V, Paliogiannis P, Casula M, Colombino M, Manca A, et al. Genetic alterations in main candidate genes during melanoma progression. Oncotarget. 2018;9:8531–8541. doi: 10.18632/oncotarget.23989. - DOI - PMC - PubMed
    1. Ombra MN, Paliogiannis P, Doneddu V, Sini MC, Colombino M, Rozzo C, et al. Vitamin D status and risk for malignant cutaneous melanoma: recent advances. Eur J Cancer Prev. 2017;26:532–541. doi: 10.1097/CEJ.0000000000000334. - DOI - PMC - PubMed
    1. Jacinto FA, Fisher GH, Espana EM, Leyngold IM, Margo CE. Separate primary melanomas of the bulbar conjunctiva and eyelid skin: clinical implications of multiple primary melanomas. Ocul Oncol Pathol. 2016;2:226–229. doi: 10.1159/000445543. - DOI - PMC - PubMed
    1. Utjés D, Lyth J, Lapins J, Eriksson H. Reduced disease-specific survival following a diagnosis of multiple primary cutaneous malignant melanomas-a nationwide, population-based study. Int J Cancer. 2017;141:2243–2252. doi: 10.1002/ijc.30925. - DOI - PubMed

MeSH terms

Substances

Grants and funding